“Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s573. doi:10.25251/skin.10.supp.573.